TITLE:
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

CONDITION:
Liver Neoplasms

INTERVENTION:
Seocalcitol

SUMMARY:

      To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended
      curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol
      injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation
      therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Hospital in- or out patients

          -  Either sex

          -  18 to 75 years of age

          -  With hepatocellular carcinoma treated successfully with surgical resection or
             percutaneous ablative treatment within 4 and 8 weeks, respectively, prior to
             inclusion.

          -  All patients must give their signed informed consent to join the study.

        Exclusion Criteria:

          -  Patients previously treated with any anti-cancer therapy for HCC except for surgical
             resection and percutaneous ablative therapy

          -  Patients treated with chemotherapy or other anti-cancer therapy (except surgical
             resection or percutaneous ablative treatment) in the previous 4 weeks

          -  Patients with another primary tumor except basocellular carcinoma of the skin or in
             situ carcinoma of the cervix within the last 2 years

          -  With a history of renal stone(s)

          -  With a life expectancy < 3 months

          -  WHO performance status 3 or 4.

          -  Patients with hypercalcemia (ionised serum calcium > 1.35 mmol/l or albumin corrected
             serum calcium > 2.68 mmol/l), previous/current calcium metabolic disease, taking
             calcium-lowering therapy or medication known to affect systemic calcium metabolism,
             or with marked laboratory abnormalities.

          -  Patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases,
             Okuda stage III disease and patients with a Child-Pugh score of C are also excluded.
      
